{"product_id":"alfasigma-bcg-matrix","title":"Alfasigma Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDownload Your Competitive Advantage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eAlfasigma’s preliminary BCG Matrix highlights a mixed portfolio—core brands showing strong market share in mature segments (potential Cash Cows) while innovation-driven lines sit as Question Marks with high growth potential but uncertain payoff; a few legacy SKUs lean toward Dog territory and may warrant divestment. Dive deeper into this company’s BCG Matrix and gain a clear view of where its products stand—Stars, Cash Cows, Dogs, or Question Marks. Purchase the full version for a complete breakdown and strategic insights you can act on.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFilgotinib Specialty Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFollowing Alfasigma’s strategic acquisition of the Jyseleca (filgotinib) franchise in 2024, the product sits firmly as a Star in the BCG matrix, driving double-digit growth in the JAK inhibitor class for rheumatoid arthritis and ulcerative colitis.\u003c\/p\u003e\n\u003cp\u003eBy Q4 2025 filgotinib generated ~€420m annualized sales for Alfasigma, achieving 18% market share versus TNF biologics in key European markets and growing at ~32% YoY.\u003c\/p\u003e\n\u003cp\u003eAlfasigma’s €65m annual investment in specialist sales and KOL programs is justified by rapid uptake—prescriber penetration rose from 12% to 38% in major EU5 markets within 18 months.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Microbiome Therapeutics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Yovis brand has evolved from a standard probiotic into a premium, microbiome-focused range, holding a leading share in Alfasigma’s gut-health portfolio and targeting a global digestive wellness market projected at USD 83.5 billion by 2026 (OECD\/Grand View Research).\u003c\/p\u003e\n\u003cp\u003eThese advanced therapeutics sit in the BCG Matrix as a Star: high market growth (CAGR ~7.8% 2021–26) and strong relative market share driven by proprietary strains and formulation tech.\u003c\/p\u003e\n\u003cp\u003eAlfasigma’s ongoing capex—≈€15–20m annually since 2023 for clinical trials and R\u0026amp;D—supports clinical validation, keeping Yovis the preferred option among HCPs and premium consumers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic US Market Entry Assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAlfasigma has launched specialty gastroenterology products in North America, posting compounded annual growth rates near 45% since 2022 and reaching ~$120m in 2025 revenue in the region.\u003c\/p\u003e\n\u003cp\u003eThese assets are in a high-investment phase—~$40m capex and $25m annual marketing in 2025—to build distribution and compete with US incumbents.\u003c\/p\u003e\n\u003cp\u003eHigh US market-share potential (projected 20–25% in target niches by 2030) makes them stars expected to become cash cows by decade end.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNext-Generation Vascular Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNext-Generation Vascular Solutions builds on Alfasigma’s legacy vascular portfolio with bio-active treatments for chronic venous disorders that reached €45m in 2025 sales, growing ~28% YoY amid a global age 65+ population increase to 9.6% in 2025 and rising venous disease diagnoses.\u003c\/p\u003e\n\u003cp\u003eThese products sit in a high-growth segment; they demand heavy R\u0026amp;D (≈€12m annually) but secure market leadership in specialty vascular care, creating a durable competitive moat through clinical data and specialist channels.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2025 sales €45m, +28% YoY\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D ≈€12m\/year\u003c\/li\u003e\n\u003cli\u003eGlobal 65+ = 9.6% (2025)\u003c\/li\u003e\n\u003cli\u003eHigh diagnosis rates → expanding TAM\u003c\/li\u003e\n\u003cli\u003eSpecialty leadership = competitive moat\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital-Channel Specialty Injectables\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAlfasigma’s move into hospital-channel specialty injectables for acute gastrointestinal (GI) care has delivered a dominant clinical position, with hospital sales up ~28% year-on-year and injectables now ~18% of group revenue (2024 financials).\u003c\/p\u003e\n\u003cp\u003eHigh entry barriers—stringent GMP, cold-chain logistics, and formulary approvals—plus a 12% CAGR in inpatient targeted-therapy demand (2021–24) keep this a BCG Star.\u003c\/p\u003e\n\u003cp\u003eAlfasigma is expanding capacity with a €45m 2024 plant upgrade and multi-year procurement deals covering 60% of top-tier Italian hospitals to defend share.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRevenue mix: injectables ~18% of group (2024)\u003c\/li\u003e\n\u003cli\u003eGrowth: ~28% YoY hospital sales increase (2024)\u003c\/li\u003e\n\u003cli\u003eCAGR inpatient demand: 12% (2021–24)\u003c\/li\u003e\n\u003cli\u003eCapex: €45m plant upgrade (2024)\u003c\/li\u003e\n\u003cli\u003eProcurement coverage: 60% top-tier Italian hospitals\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlfasigma’s high-growth portfolio fuels reinvestment to secure 2030 cash-cow leadership\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAlfasigma’s Stars—filgotinib, Yovis premium range, Next-Gen Vascular, and hospital GI injectables—deliver high growth (filgotinib €420m, +32% YoY; Yovis global market target USD 83.5bn; Vascular €45m, +28% YoY; injectables ~18% group rev) and heavy reinvestment (sales \u0026amp; marketing €65m; R\u0026amp;D\/clinical €15–20m; capex €45m) to secure leadership and transition to cash cows by 2030.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003e2025 Sales\u003c\/th\u003e\n\u003cth\u003eYoY%\u003c\/th\u003e\n\u003cth\u003eCapex\/R\u0026amp;D\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFilgotinib\u003c\/td\u003e\n\u003ctd\u003e€420m\u003c\/td\u003e\n\u003ctd\u003e+32%\u003c\/td\u003e\n\u003ctd\u003e€65m S\u0026amp;M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eYovis\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003e€15–20m R\u0026amp;D\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVascular\u003c\/td\u003e\n\u003ctd\u003e€45m\u003c\/td\u003e\n\u003ctd\u003e+28%\u003c\/td\u003e\n\u003ctd\u003e€12m R\u0026amp;D\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInjectables\u003c\/td\u003e\n\u003ctd\u003e~18% group rev\u003c\/td\u003e\n\u003ctd\u003e~+28%\u003c\/td\u003e\n\u003ctd\u003e€45m capex\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG Matrix review of Alfasigma’s portfolio with quadrant-specific strategies, risks, and investment recommendations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page Alfasigma BCG Matrix placing each business unit in a quadrant for clear strategic decisions\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNormix Rifaximin Flagship\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNormix (rifaximin) remains Alfasigma’s flagship cash cow, generating roughly €350–400m in annual revenues in 2025 and holding over 60% global market share in hepatic encephalopathy and ~50% in IBS-D.\u003c\/p\u003e\n\u003cp\u003eIn the mature pharma market, Normix needs relatively low marketing spend—around 5–7% of sales—yielding high free cash flow margins near 30%.\u003c\/p\u003e\n\u003cp\u003eThose cash flows are pivotal for servicing ~€700m of corporate debt and funding acquisitions of biotech assets, which accounted for €150m of spend in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVessel Due F Vascular Range\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVessel Due F (sulodexide) remains Alfasigma’s cash cow in the mature vascular market, holding ~35% market share in Europe and 28% in Asia as of 2025 and generating roughly €120m annual sales, with stable year-on-year growth ~2%. \u003c\/p\u003e\n\u003cp\u003eIts proven efficacy drives high patient loyalty and steady prescribing, keeping marketing spend low (marketing-to-sales ~6%), freeing cash to fund Alfasigma’s digital health and rare-disease R\u0026amp;D programs. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiochetasi Digestive Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBiochetasi Digestive Portfolio holds a leading share (\u0026gt;40% in Italy; 30–35% across key Mediterranean markets in 2024) in the OTC gastric-upset segment, making it a household name. The category shows low single-digit CAGR (~1–2% annual growth), but margins run high: EBITDA margins around 28% in 2024 thanks to optimized manufacturing and a lean supply chain. It generates steady free cash flow (~€35–45m annually in 2024–25), funding Alfasigma’s consumer health R\u0026amp;D and new product launches.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNeo-Borocillina Throat Care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eNeo-Borocillina Throat Care is a market leader in respiratory OTCs, delivering steady seasonal revenue peaks and high operating margins—reported around 18–22% EBITDA in 2024—while needing minimal capital reinvestment.\u003c\/p\u003e\n\u003cp\u003eThe brand’s strong equity supports premium pricing versus generics, preserving margin and cash flow; Alfasigma redirects these cash flows—estimated €20–30M annually in 2024—into high-growth nutraceutical question marks.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket leader in respiratory OTCs\u003c\/li\u003e\n\u003cli\u003eSeasonal cash peaks, low capex\u003c\/li\u003e\n\u003cli\u003eEBITDA ~18–22% (2024)\u003c\/li\u003e\n\u003cli\u003ePremium pricing vs generics\u003c\/li\u003e\n\u003cli\u003e€20–30M redirected to nutraceuticals (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Development and Manufacturing Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAlfasigma’s Contract Development and Manufacturing Organization (CDMO) arm, run from fully accredited Italian plants, delivers specialized outsourced services to third-party pharma clients and generated roughly €220m in 2024 revenue, producing steady, predictable cash flow.\u003c\/p\u003e\n\u003cp\u003eThe unit holds a regional market-leading share in niche specialized manufacturing where annual growth has stabilized near 2–3% and capacity utilization exceeds 85%.\u003c\/p\u003e\n\u003cp\u003eWith core plant assets fully depreciated, Alfasigma extracts high operating margins (estimated EBITDA margin ~28% in 2024), funding R\u0026amp;D and M\u0026amp;A without heavy capital outlay.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 revenue ~€220m\u003c\/li\u003e\n\u003cli\u003eEBITDA margin ~28%\u003c\/li\u003e\n\u003cli\u003eCapacity utilization \u0026gt;85%\u003c\/li\u003e\n\u003cli\u003eRegional market share leader; growth 2–3%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-margin pharma portfolio: Normix €375m, CDMO €220m, strong FCF across brands\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNormix: €375m rev (2025 est), \u0026gt;60% HE share, FCF margin ~30%; Vessel Due F: €120m (2025), EU share ~35%, growth ~2%; Biochetasi: €40–45m FCF (2024–25), Italy share \u0026gt;40%; Neo-Borocillina: €25m FCF (2024), EBITDA 18–22%; CDMO: €220m rev (2024), EBITDA ~28%, utilization \u0026gt;85%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eRev\/FCF\u003c\/th\u003e\n\u003cth\u003eMarket share\u003c\/th\u003e\n\u003cth\u003eEBITDA\/FCF%\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNormix\u003c\/td\u003e\n\u003ctd\u003e€375m\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;60% HE\u003c\/td\u003e\n\u003ctd\u003e30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVessel Due F\u003c\/td\u003e\n\u003ctd\u003e€120m\u003c\/td\u003e\n\u003ctd\u003e35% EU\u003c\/td\u003e\n\u003ctd\u003e~6% mkt spend\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiochetasi\u003c\/td\u003e\n\u003ctd\u003e€40–45m FCF\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;40% IT\u003c\/td\u003e\n\u003ctd\u003e28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNeo-Borocillina\u003c\/td\u003e\n\u003ctd\u003e€25m FCF\u003c\/td\u003e\n\u003ctd\u003eLeader OTC\u003c\/td\u003e\n\u003ctd\u003e18–22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDMO\u003c\/td\u003e\n\u003ctd\u003e€220m\u003c\/td\u003e\n\u003ctd\u003eRegional leader\u003c\/td\u003e\n\u003ctd\u003e28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Shown\u003c\/span\u003e\u003cbr\u003eAlfasigma BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing on this page is the exact Alfasigma BCG Matrix report you'll receive after purchase—no watermarks, no demo content, just the fully formatted, presentation-ready analysis tailored for strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56748538823033,"sku":"alfasigma-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/alfasigma-bcg-matrix.png?v=1772209295","url":"https:\/\/matrixbcg.com\/products\/alfasigma-bcg-matrix","provider":"MatrixBCG","version":"1.0","type":"link"}